Chromosomal Microarray Analysis (CMA)

To understand CMA, imagine comparing a map of a whole city to a detailed satellite view that can see individual houses. Traditional karyotyping is like the city map; it shows the big picture (extra or missing whole chromosomes like in Down syndrome) but misses the small details. CMA is the satellite view. It uses thousands of DNA probes to identify 'copy number variations' (CNVs).

CNVs occur when pieces of a chromosome are either missing (a deletion) or extra (a duplication). Because DNA is the instruction manual for the body, even a very small missing instruction can lead to complex health outcomes. At the MFM Unit, CMA has largely replaced conventional karyotyping for diagnostic cases because it provides a 6% to 10% increase in the detection of significant genetic conditions that would otherwise go unrecognized.

CMA is recommended when a woman undergoes an invasive diagnostic procedure (CVS or Amniocentesis). It is particularly vital in situations where:

• A structural anomaly is found on ultrasound: For example, a heart defect, a brain variation, or skeletal issues. In these cases, 1 in 10 to 1 in 20 babies will have a finding on CMA that standard tests miss.
• Increased Nuchal Translucency: Even if the rapid test (QF-PCR) is normal, an increased NT is a strong indication for CMA.
• Unexplained fetal growth restriction: Small babies with normal Dopplers may have an underlying CNV.
• Previous family history: Of intellectual disability or developmental delay where no clear diagnosis was found.

Essentially, if you are looking for the most detailed information available about your baby's genetic health, CMA is the current international standard of care.

The testing process begins after the cells have been collected via CVS or Amniocentesis.

The Laboratory Process:

1. Extraction: Fetal DNA is extracted from the sample cells.
2. Hybridization: The fetal DNA is compared to a 'normal' reference DNA sample. They are mixed together and placed on a specialized 'microarray chip'.
3. Scanning: A laser scanner reads the chip. If the fetal DNA and reference DNA match perfectly, the signal is balanced. If there is more fetal DNA, it indicates a duplication; if there is less, it indicates a deletion.
4. Bioinformatics Analysis: Clinical geneticists and MFM subspecialists then interpret these findings to determine if they are clinically significant. This deep analysis is why the final report typically takes 10 to 14 days.

Management following a CMA result follows a structured three-tier pathway:

• Normal Result: This is the most common outcome and provides a high level of reassurance, indicating that no significant gains or losses were detected at a high-resolution level.
• Pathogenic Finding: This means a variation was found that is known to cause a specific syndrome (e.g., DiGeorge syndrome). We immediately coordinate with pediatric specialists and genetic counselors to explain the finding and plan the best possible care for the pregnancy and delivery.
• Variant of Uncertain Significance (VUS): This is the most complex result. It means a change was found, but it is not yet clearly understood by medical science. In these cases, we often test the parents to see if they carry the same variation. If a healthy parent has the same VUS, it is much more likely to be a benign family trait rather than a problem for the baby.

The outcome of CMA is a profound increase in diagnostic precision. For families where a baby has a structural defect, knowing the exact genetic cause allows for precise 'prognostic' counseling. This means we can tell you with much more accuracy what the baby might need after birth—whether it is cardiology, neurology, or early developmental support.

Furthermore, for many families, a normal CMA result provides the clinical confidence to continue a pregnancy that might have otherwise been clouded by uncertainty. It is a tool that replaces fear and speculation with hard, molecular evidence, ensuring that every decision made is based on the best available data.

If you are planning an invasive procedure (CVS or Amniocentesis) anywhere in the UAE, you should inquire whether Chromosomal Microarray is included. At the MFM Unit, we prioritize CMA for all diagnostic cases because the 'resolution' of the information is vastly superior to older methods.

If you have already had an amniocentesis elsewhere that was 'normal' but your baby still has a suspected issue on ultrasound, you should seek an immediate referral to our subspecialists. We can often perform a secondary analysis or 'extended' genetic testing to find the answers that standard laboratories might have missed.